middle.news
Mayne Pharma clears final IMVEXXY patent dispute with Teva
9:43am on Friday 16th of October, 2026 AEDT
•
Pharmaceuticals
Read Story
Mayne Pharma clears final IMVEXXY patent dispute with Teva
9:43am on Friday 16th of October, 2026 AEDT
Key Points
Teva generic entry potentially set for 2 September 2032
Settlement resolves Mayne Pharma’s final IMVEXXY Paragraph IV dispute
No financial payment or upfront consideration between the parties
IMVEXXY net sales rose 8% to US$29.3 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE